Indication: COVID

A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19

Sub-indication: COVID-19 Infection

Study Type: Drug Study

Principal Investigator: Kristina Bryant, M.D.
Norton Children's Infectious Diseases, affiliated with the UofL School of Medicine

Sponsor: Sponsor: Gilead Sciences, Inc

Learn more at ClinicalTrials.gov

Email for more information: NCRI-ID@NortonHealthcare.org

Search our entire site.